Our subgroup analysis found that SGLT2 inhibitors reduce the risk of MACEs, CV death, all-cause death, and HHF in diabetic patients; reduce the risk of MACEs, CV death, MI, all-cause death, and HHF in people with a high risk of ACD; reduce the risk of all-cause death, CV death, HHF and other risks of patients with ACD and HF; and reduce the risk of MACEs, CV death, HHF and other risks in CKD patients. The gene discussed is SLC5A2; the disease is chronic kidney disease.